U.S. Sees Historic Drop in Overdose Deaths in 2025

Signs at a health event in Charleston, W.Va., showcase the importance of naloxone, or Narcan, in reducing overdose deaths. Public health officials report a significant decline in street drug fatalities in the U.S. The Centers for Disease Control and Prevention (CDC) indicates a 14% decrease in overdose deaths in 2025 compared to 2024. In total, 69,973 people died from overdoses last year, marking a reduction of around 11,300 deaths from the previous year.

Dr. Nora Volkow, head of the U.S. National Institute on Drug Abuse (NIDA), expressed optimism about the trend. “This is very good news,” she remarked. The decrease began in 2023, but its sustainability was uncertain at that time. Experts attribute the decline to increased use of medications that alleviate opioid cravings and reverse overdoses.

Beth Meyerson, a drug policy researcher in Arizona, highlighted the role of naloxone. “Access to naloxone has become widespread,” she stated, describing it as critical first aid in overdose situations. The decline in overdose deaths started in the summer of 2023, driven by factors like lower potency fentanyl and decreased drug use among young people.

Certain states, including Alabama, New York, and Virginia, showed significant reductions in overdose deaths, with drops between 25-30%. New York Governor Kathy Hochul noted a significant reduction in opioid deaths from fentanyl, heroin, and illegally sold pain pills since 2022. She emphasized continuing efforts to address health disparities and emerging drug threats.

“Seeing this national decline, we should definitely be happy because we know some structural things have made a difference,” said Beth Meyerson.

The year 2025 recorded the lowest level of drug deaths in the U.S. since at least 2019, a significant decrease from the peak of 112,418 deaths in summer 2023. However, some troubling trends persist. Compared to other countries, the U.S. still faces high drug death rates. Scotland, second to the U.S. in drug death rates, reported significantly lower fatalities per capita.

Older Americans and communities predominantly with Black and Native American populations continue to experience high overdose death rates. New synthetic drugs, derived from industrial chemicals, exacerbate the issue. States such as Arizona, New Mexico, and North Dakota reported increases in fatalities in 2025.

Meyerson pointed out the lack of access to medical care and the presence of potent fentanyl and methamphetamines in Arizona. She highlighted the over two-hour travel time required for opioid treatment in rural areas. Dr. Volkow acknowledged the issues in Arizona and New Mexico, noting that Native American communities face overdose mortality rates twice that of the national average. More efforts are necessary to improve medical care access in these regions.